Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
PMV Pharmaceuticals, Inc
University of California, Irvine
Eli Lilly and Company
ViroMissile, Inc.
AstraZeneca
Tizona Therapeutics, Inc
IDEAYA Biosciences
University of Colorado, Denver
Institut Curie
Theravectys S.A.
Karolinska University Hospital
Daiichi Sankyo
Adela, Inc
Perspective Therapeutics
Elephas
Elephas
Massive Bio, Inc.
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Maastricht University Medical Center
LigaChem Biosciences, Inc.
Washington University School of Medicine
Institut Claudius Regaud
Bicara Therapeutics
The Netherlands Cancer Institute
Marengo Therapeutics, Inc.
University of California, Irvine
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
UNICANCER
Cofactor Genomics, Inc.
University Health Network, Toronto
Pack Health
Varian, a Siemens Healthineers Company
The Affiliated Hospital of Qingdao University
Second Affiliated Hospital of Guangzhou Medical University
University College, London
Innolake Biopharm
GeneMedicine Co., Ltd.
Charite University, Berlin, Germany
Hospices Civils de Lyon